Caribou Biosciences, Inc. (CRBU) News

Caribou Biosciences, Inc. (CRBU): $5.80

0.14 (+2.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRBU to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Filter CRBU News Items

CRBU News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CRBU News Highlights

  • For CRBU, its 30 day story count is now at 2.
  • Over the past 15 days, the trend for CRBU's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about CRBU are AR.

Latest CRBU News From Around the Web

Below are the latest news stories about Caribou Biosciences Inc that investors may wish to consider to help them evaluate CRBU as an investment opportunity.

10 Biotech Stocks to Sell Now According to Cathie Wood

In this article, we discuss 10 biotech stocks to sell now according to Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to 5 Biotech Stocks to Sell Now According to Cathie Wood. The mass sell-off of stocks in the high growth sector has not been very kind to […]

Yahoo | February 22, 2022

Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17th, at 2:20 pm ET. A live webcast of the discussion will be accessible via Caribou’s website on the Events page. The ar

Yahoo | February 7, 2022

Is Caribou Biosciences, Inc. (NASDAQ:CRBU) Popular Amongst Insiders?

Every investor in Caribou Biosciences, Inc. ( NASDAQ:CRBU ) should be aware of the most powerful shareholder groups...

Yahoo | January 21, 2022

Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer

Dr. Rizvi brings significant experience in oncology cell therapy developmentBERKELEY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Syed Rizvi, M.D., to the newly created position of chief medical officer. Dr. Rizvi has more than two decades of experience in all stages of drug development, from clinical strategy and execution through regulatory submis

Yahoo | January 18, 2022

Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 am ET. A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The archived

Yahoo | January 4, 2022

Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc

Investment company Destra Investment Trust (Current Portfolio) buys ThredUp Inc, Etsy Inc, Riskified, Luxfer Holdings PLC, Spero Therapeutics Inc, sells , , 2U Inc, Euronet Worldwide Inc, Sapiens International Corp NV during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Destra Investment Trust.

Yahoo | December 28, 2021

Hedge Funds Are Crazy About Caribou Biosciences Inc. (CRBU)

In this article we will analyze whether Caribou Biosciences Inc. (NASDAQ:CRBU) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]

Yahoo | December 12, 2021

Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ...

Investment company Tekla Life Sciences Investors (Current Portfolio) buys Amgen Inc, Alkermes PLC, Novavax Inc, Intra-Cellular Therapies Inc, AstraZeneca PLC, sells Moderna Inc, Allakos Inc, Blueprint Medicines Corp, Ascendis Pharma A/S, BridgeBio Pharma Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Tekla Life Sciences Investors.

Yahoo | December 9, 2021

Tekla Healthcare Investors Buys Amgen Inc, Guardant Health Inc, Icon PLC, Sells Abbott ...

Investment company Tekla Healthcare Investors (Current Portfolio) buys Amgen Inc, Guardant Health Inc, Icon PLC, IDEXX Laboratories Inc, Alnylam Pharmaceuticals Inc, sells Abbott Laboratories, Deciphera Pharmaceuticals Inc, BridgeBio Pharma Inc, Ascendis Pharma A/S, ResMed Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Tekla Healthcare Investors.

Yahoo | December 9, 2021

Analysts’ Top Healthcare Picks: Vir Biotechnology (VIR), Blueprint Medicines (BPMC)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR – Research Report), Blueprint Medicines (BPMC – Research Report) and Caribou Biosciences (CRBU – Research Report) with bullish sentiments. Vir Biotechnology (VIR) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Vir Biotechnology, with a price target of $200.00. The company's shares closed last Monday at $40.48, close to its 52-week low of $25.31. According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of -11.2% and a 24.1% success rate.

Catie Powers on TipRanks | November 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3729 seconds.